An Epidemiological Registry Study to Evaluate Clinical Practice Treatment in Patients With Bipolar Disorder (REED)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01455961
First received: October 17, 2011
Last updated: August 20, 2014
Last verified: August 2014

October 17, 2011
August 20, 2014
November 2011
April 2012   (final data collection date for primary outcome measure)
Description of detailed clinical treatment in terms of duration of treatment, doses, drug switches, and add-on therapy, in patients with BD and on treatment with quetiapine XR and/or quetiapine IR before, at and after the index date. [ Time Frame: 1st of January 2009 to 31st of December 2010. ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01455961 on ClinicalTrials.gov Archive Site
  • Description of co-morbidity, demographics, sick leave, early retirement and socioeconomic factors in patients with BD and on treatment with quetiapine XR and/or quetiapine IR before and at the index date. [ Time Frame: 1st of January 2009 to 31st of December 2010. ] [ Designated as safety issue: No ]
  • Description of the detailed clinical treatment in terms of duration of treatment, doses, drug switches, and add-on therapy, in patients with BD, including all drug treatment after the index date [ Time Frame: 1st of January 2009 to 31st of December 2010. ] [ Designated as safety issue: No ]
  • Description of co-morbidity, demographics, sick leave, early retirement and socioeconomic factors in patients with BD, including all drug treatment before and at the index date [ Time Frame: 1st of January 2009 to 31st of December 2010. ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
An Epidemiological Registry Study to Evaluate Clinical Practice Treatment in Patients With Bipolar Disorder
An Epidemiological Registry Study to Evaluate Clinical Practice Treatment in Patients With Bipolar Disorder Treated With Quetiapine XR and/or Quetiapine IR

The aim of this study is to describe the treatment pattern and patient characteristics in real life setting in patients with Bipolar disorder treated with Seroquel XR and/or Seroquel IR in Sweden.

An epidemiological registry study to evaluate clinical practice treatment in patients with Bipolar Disorder treated with quetiapine XR and/or quetiapine IR

Observational
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample

All patients who have been hospitalised in Sweden at least once since 1987 with a diagnosis during hospitalisation of Bipolar Disorder.

Bipolar Disorder
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
16000
April 2012
April 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with a diagnosis of BD.

Exclusion Criteria:

  • Patients with a diagnosis of any schizophrenia spectrum disorder after the diagnosis of bipolar disorder.
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01455961
VD-NS-1101
No
AstraZeneca
AstraZeneca
Not Provided
Principal Investigator: Andreas Carlborg, MD Department of Clinical Neuroscience, Karolinska Institutet 171 76 Stockholm
AstraZeneca
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP